Issue date: 2020.05.28
Release date: 2020.05.29
Survey of COVID-19 R&D is now open.
Artificial intelligence (AI) contributes to COVID-19 infection control in various aspects such as therapeutic drug development, infection simulation, and remote environmental treatment. As the first initiative, AI Japan conducted a survey of relevant R&D activities to member universities and public institutions. As the result, 61 registrations from 23 universities / organizations have been made and we are happy to disclose here. Going forward, we plan to continue to investigate related efforts and make announcements at any time, and promote to provide opportunities for collaboration of AI research and development in Japan.